Skip to main content
Log in

Neues von Prolaktin

New aspects of prolactin

  • Leitthema
  • Published:
Gynäkologische Endokrinologie Aims and scope

Zusammenfassung

Sekundäre Amenorrhö und Infertilität sind ein häufiger Konsultationsgrund. Eine Hyperprolaktinämie muss ätiologisch immer ausgeschlossen werden. Prolaktinome stellen die häufigste Ursache einer symptomatischen Hyperprolaktinämie dar. Therapeutisch werden hier primär Dopaminagonisten eingesetzt, die meist zu einer Normalisierung von Prolaktin und daraufhin zur Wiederherstellung von ovulatorischen Zyklen führen. Ebenfalls häufig ist die medikamentös bedingte Hyperprolaktinämie, die am häufigsten durch Neuroleptika (D2-Antagonisten) bedingt ist, aber auch durch andere Medikamentenklassen verursacht werden kann. Das Ausmaß der Hyperprolaktinämie kann auch bei neueren Neuroleptika unterschiedlich sein. Nach Ausschluss eines Prolaktinoms und bei negativer Medikamentenanamnese sollte an seltenere Ursachen einer Hyperprolaktinämie gedacht werden. Schließlich sollten gewisse labortechnische Fallen bei der Interpretation von Prolaktinwerten in Betracht gezogen werden (Makroprolaktin, Hook-Effekt).

Abstract

Secondary amenorrhea and infertility are frequent reasons for consultation. Hyperprolactinemia must always be ruled out as a possible etiology. Prolactinomas represent the most common cause of symptomatic hyperprolactinemia and dopamine agonists are the first line therapy, mostly leading to a normalization of prolactin levels and restoration of ovulatory cycles. Drug-induced hyperprolactinemia is also common, particularly with neuroleptic drugs (D2 antagonists) but also with other mainly psychotropic drug classes: however, the degree of prolactin elevation can vary considerably even with the use of newer neuroleptic drugs. If a prolactinoma has been ruled out and medication history is not contributory, rarer causes of hyperprolactinemia should be considered. Finally, analytical pitfalls should be taken into account in the interpretation of prolactin levels (e.g. macroprolactin and the hook effect).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Grattan DR (2015) 60 Years of neuroendocrinology: The hypothalamo-prolactin axis. J Endocrinol 226(2):T101–T122

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Grattan DR (2008) Pregnancy-induced adaptation in the neuroendocrine control of prolactin secretion. J Neuroendocrinol 20(4):497–507

    Article  CAS  PubMed  Google Scholar 

  3. Torner L (2002) The brain prolactin system: Involvement in stress response adaptations in lactation. Stress 5(4):249–257

    Article  CAS  PubMed  Google Scholar 

  4. Wong A (2015) Update on prolactinomas. Part 1: Clinical manifestations and diagnostic challenges. J Clin Neurosci 22(10):1562–1567 (Oct)

    Article  PubMed  Google Scholar 

  5. Melmed S (2011) Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273–288

    Article  CAS  PubMed  Google Scholar 

  6. Glezer A (2015) Prolactinomas. Endocrinol Metab Clin North Am 44(1):71–78

    Article  PubMed  Google Scholar 

  7. Webster J (1999) Dopamine agonist therapy in hyperprolactinemia. J Reprod Med 44(12 Suppl):1105–1110

    CAS  PubMed  Google Scholar 

  8. Wong A (2015) Update on prolactinomas. Part 2: Treatment and management strategies. J Clin Neurosci 22(10):1568–1574

    Article  PubMed  Google Scholar 

  9. Webster J (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331(14):904–909

    Article  CAS  PubMed  Google Scholar 

  10. De Vecchis R, Esposito C, Ariano C (2013) Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies. Herz 38(6):618–628

    Article  PubMed  Google Scholar 

  11. Drake WM, Stiles CE, Howlett TA, Toogood AA, Bevan JS, Steeds RP, UK Dopamine Agonist Valvulopathy Group (2014) A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J Clin Endocrinol Metab 99(1):90–96

    Article  CAS  PubMed  Google Scholar 

  12. Colao A (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349(21):2023–2033

    Article  CAS  PubMed  Google Scholar 

  13. Smith TR (2015) Current indications for the surgical treatment of prolactinomas. J Clin Neurosci 22(11):1785–1791

    Article  PubMed  Google Scholar 

  14. Liu JK (2004) Contemporary management of prolactinomas. Neurosurg Focus 16(4):E2

    Article  PubMed  Google Scholar 

  15. Mallea-Gil MS (2016) Prolactinomas: Evolution after menopause. Arch Endocrinol Metab 60(1):42–46

    Article  PubMed  Google Scholar 

  16. Faje AT (2015) The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: Cons. Endocrine 48(1):79–82

    Article  CAS  PubMed  Google Scholar 

  17. Peuskens J (2014) The effect of novel and newly approved antipsychotics on serum prolactin levels: A comprehensive review. CNS Drugs 28(5):421–453

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Newey PJ (2013) Mutant prolactin receptor and familial hyperprolactinemia. N Engl J Med 369:2012–2020

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Snyder PJ (1973) Thyroid hormone inhibition of the prolactin response to thyrotropin-releasing hormone. J Clin Invest 52(9):2324–2329

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Grubb MR (1987) Patients with primary hypothyroidism presenting as prolactinomas. Am J Med 83(4):765–769

    Article  CAS  PubMed  Google Scholar 

  21. Ress C (2014) Serum prolactin in advanced chronic liver disease. Horm Metab Res 46(11):800–803

    Article  CAS  PubMed  Google Scholar 

  22. Holley JL (2004) The hypothalamic-pituitary axis in men and women with chronic kidney disease. Adv Chronic Kidney Dis 11(4):337–341

    Article  PubMed  Google Scholar 

  23. Olukoga AO (1999) Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol (Oxf) 51(1):119–126

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to E. Christ MD, PhD.

Ethics declarations

Interessenkonflikt

S. Bervini, L. Valente und E. Christ geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

W. Rossmanith, Baden-Baden/Bühl

C. Schöfl, Herzogenaurach

T. Strowitzki, Heidelberg

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bervini, S., Valente, L. & Christ, E. Neues von Prolaktin. Gynäkologische Endokrinologie 14, 239–244 (2016). https://doi.org/10.1007/s10304-016-0093-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10304-016-0093-z

Schlüsselwörter

Keywords

Navigation